CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
暂无分享，去创建一个
I. Bernstein | S. Raimondi | R. Ries | S. Meshinchi | T. Alonzo | M. Loken | B. Hirsch | R. Walter | R. Aplenc | J. Lamba | A. Gamis | J. Pollard | Lata Chauhan | Yi-Cheng Wang | Miyoung Shin